Senti Bio Appoints Feng Hsiung to Board of Directors

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [5] - The company aims to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [5] Leadership Appointment - Feng Hsiung has been appointed to the Board of Directors, effective March 7, 2025, bringing extensive experience in investment strategy and capital markets [2][3] - Hsiung is the Founder and Chief Investment Officer of Acion Partners and has held significant roles at York Capital, contributing to his expertise in various industries [2] Stock Options Grant - On March 7, 2025, the Board granted stock options to three new employees, totaling 202,700 shares with an exercise price of $3.52 per share [4] - The majority of these options, 174,200, were awarded to the new Chief Financial Officer, Jay Cross, under the 2022 Inducement Equity Plan [4]